SF3B1 and B-cell chronic lymphocytic leukemia: Given that SF3B1 mutation and del(13q) activate the mTORC1 pathway through RNA splicing, we hypothesized that DM CLL cells are sensitive to either RNA splicing inhibitor or mTORC1 inhibitor treatment.